Pseudomonas aeruginosa — Competitive Intelligence Brief

Pseudomonas aeruginosa (Pseudomonas aeruginosa) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: beta-lactam antibiotic. Area: Infectious disease.

marketed beta-lactam antibiotic penicillin-binding proteins Infectious disease Small molecule

Target snapshot

Pseudomonas aeruginosa (Pseudomonas aeruginosa) — Qilu Hospital of Shandong University. Pseudomonas aeruginosa is a broad-spectrum antibiotic that targets bacterial cell wall synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pseudomonas aeruginosa TARGET	Pseudomonas aeruginosa	Qilu Hospital of Shandong University	marketed	beta-lactam antibiotic	penicillin-binding proteins
CEPHALEXIN	CEPHALEXIN		marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)	1971-01-01
I.V ampicillin 2 gram x4/d for 2 days	I.V ampicillin 2 gram x4/d for 2 days	Western Galilee Hospital-Nahariya	marketed	Beta-lactam antibiotic (aminopenicillin)	Penicillin-binding proteins (PBPs); bacterial peptidoglycan
Beta-lactam antibiotic	Beta-lactam antibiotic	University Hospital, Ghent	marketed	Beta-lactam antibiotic	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
omeprazole plus amoxicillin	omeprazole plus amoxicillin	National Taiwan University Hospital	marketed	Proton pump inhibitor + beta-lactam antibiotic combination	Proton pump (H+/K+-ATPase) and bacterial cell wall (penicillin-binding proteins)
Colistin/Polymyxin B + Meropenem	Colistin/Polymyxin B + Meropenem	National University of Singapore	marketed	Antibiotic combination (polymyxin + carbapenem)	Bacterial cell membrane (polymyxins) and bacterial cell wall/penicillin-binding proteins (meropenem)
Cefepime, Meropenem, or Piperacillin/Tazobactam	Cefepime, Meropenem, or Piperacillin/Tazobactam	University of Florida	marketed	Beta-lactam antibiotic (cephalosporin, carbapenem, or aminopenicillin with beta-lactamase inhibitor)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (beta-lactam antibiotic class)

1. Allecra · 1 drug in this class
2. Qilu Hospital of Shandong University · 1 drug in this class